Mariana Gomez de la Espriella

Mariana Gomez de la Espriella

Auto-generated profile, based on publicly available information

Mariana Gomez de la Espriella

Virginia Tech Carilion School of Medicine , 2 Riverside Circle , Roanoke, VA 24016

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2022 in Microbiology Resource Announcements
Verified
Journal Article
Open access
JRJayasimha Rao
Jayasimha Rao
NSNicholas K. Stornelli
Nicholas K. Stornelli
NENathan A. Everson
Nathan A. Everson
LMLauren McDaniel
Lauren McDaniel
MEMariana Gomez De La Espriella
Mariana Gomez De La Espriella
RJRoderick V Jensen
Roderick V Jensen
We report the complete genome sequence of a clinical isolate of Providencia stuartii strain CMC-4104, isolated from a splenic abscess. Oxford Nanopore Technologies (ONT) and Illumina sequencing reads were assembled using Geneious to generate a 4,504,925-bp circular chromosome containing multiple copies of the NDM-1 and PER-1 genes in a genomic resistance island.

2 November 2026 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
MEMariana Gomez de la Espriella
Mariana Gomez de la Espriella
ABAnthony Baffoe-Bonnie
Anthony Baffoe-Bonnie
CPChristopher Peterson
Christopher Peterson
JFJason R Faulhaber
Jason R Faulhaber
CRCara Ravagli
Cara Ravagli
MRMarrieth Rubio
Marrieth Rubio
Background: Chronic hepatitis C virus (HCV) infection remains a major challenge in rural US communities, where limited specialist availability restricts access to effective direct-acting antivirals (DAAs). Primary care-based HCV treatment models are clinically effective, yet uptake remains low. We implemented a training and care coordination program within our southwest Virginia health system to address this gap. Methods: We conducted a retrospective pre-post evaluation of an HCV program initiated in June 2023, comprising educational modules, webinar series, specialist consultation, and a dedicated HCV Coordinator. Adults with a qualifying HCV RNA result who initiated DAA therapy between January 1, 2022, and February 28, 2025, were included; prescribing providers were grouped by specialty (Family Medicine, Internal Medicine, or Specialist). The primary outcome was expansion of FM treatment capacity. Secondary outcomes included travel distance and time to treatment. Results: Of 828 candidate patients, 587 met eligibility criteria. FM providers initiating DAA therapy increased from 12 to 31, and clinic sites from 6 to 17. FM treatment volume increased from 13 to 40 patients (+208%), a significantly greater increase than other specialties combined (OR=2.90, p<0.001). Most newly involved FM prescribers engaged with the program, via the HCV Coordinator. Compared with specialist care, patients treated in FM had shorter travel distances (5.9 vs 18.9 miles; p<0.001) and a non-significantly shorter time to initiation (44 vs 71 days; p=0.15). Conclusions: A multifaceted implementation program combining provider education with centralized care coordination was associated with targeted expansion of FM treatment capacity and improved geographic access to HCV care.

22 September 2026 in Research Connections
Verified
Journal Article
Open access
MEMariana Gomez de la Espriella
Mariana Gomez de la Espriella
MKMerly Konathapally
Merly Konathapally
SPSarah Henrickson Parker
Sarah Henrickson Parker
CMCynthia Morrow
Cynthia Morrow
MRMarrieth Rubio
Marrieth Rubio
ABAnthony Baffoe-Bonnie
Anthony Baffoe-Bonnie
In 2024, the reported hepatitis C virus (HCV) case rate in Roanoke City was nearly three times the rate of the state of Virginia, reflecting the disproportionate impact of the opioid epidemic in the region. Despite highly effective direct-acting antiviral therapies, substantial barriers to linkage to care (LTC) persist among individuals with substance use disorders (SUDs). While prior studies suggest that patient navigation and financial support may improve LTC, evidence from rural and underserved settings remains limited. This study aims to evaluate community-based interventions designed to improve HCV LTC among individuals with SUD in Southwest Virginia. We conducted a pragmatic, non-randomized, sequential cohort pilot study to evaluate the impact of iteratively refined community-based interventions on LTC. A total of 60 adults with detectable HCV RNA and SUD were enrolled sequentially into four cohorts (control and three intervention groups). All participants received peer support; intervention components were modified across cohorts to address observed barriers to care. The primary outcome was attendance at an outpatient HCV visit within 180 days of enrolment. LTC was 3/15 (20%) in both the control group and Intervention 1, increasing to 6/15 (40%) in Intervention 2 and 11/15 (73%) in Intervention 3. Exploratory analyses demonstrated significantly higher attendance in Intervention 3 than in the control group (73% vs. 20%, P = .009). Telehealth utilization and provision of prepaid phones were incorporated in the final cohort, which demonstrated the highest LTC rate. Multicomponent community-based interventions were associated with improved LTC among individuals with SUD. Although the non-randomized sequential design limits causal attribution, the progressive improvement across cohorts provides preliminary support for a potential benefit. Interventions incorporating community navigation, telehealth access, and communication support may help address barriers to HCV treatment engagement in underserved communities.

4 December 2021 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
TFTasaduq Fazili
Tasaduq Fazili
EBEkta Bansal
Ekta Bansal
MEMariana Gomez de la Espriella
Mariana Gomez de la Espriella
DGDorothy C Garner
Dorothy C Garner
Dalbavancin is a long acting, semisynthetic derivative of teicoplanin that is currently approved for treatment of acute bacterial skin and skin structure infections. Its efficacy and role of in the treatment of invasive infections, in particular infective endocarditis, is not well known. We reviewed the English-language literature for the use of Dalbavancin in the treatment of endocarditis due to Gram-positive organisms, using Pubmed. 15 publications were reviewed. All the publications were retrospective in nature, with relatively small numbers of patients, including a few case reports. A total of 159 patients received Dalbavancin for endocarditis. The mean age was 47 years. The main reasons for using Dalbavancin were non-feasibility of a standard outpatient regimen (mainly due to drug use) or the need for a simpler regimen. 75 patients had infection of a native valve, 44 of a prosthetic valve and 19 of a cardiac device. The type of infection for the rest of the patients was not specified. The tricuspid valve was the most frequently reported. The etiologic organisms causing endocarditis were Staphylococcus species, followed by Streptococcus species and Enterococcus species, with Staphylococcus aureus being the most common. All, but one, patients received Dalbavancin as sequential therapy, after receiving other intravenous antibiotics initially. The duration of antibiotics received prior to initiation of Dalbavancin was variable, with the median being 3 weeks. The median duration of Dalbavancin use was 2.7 weeks. The dosage regimens varied, with the more common ones using a loading dose of either 1500 mg or 1000 mg, followed by one or more weekly doses of 500 mg. The overall clinical efficacy was around 89%. Adverse events were mild, including nausea, vomiting, rash, headache and reversible acute kidney injury. None of the patients had to discontinue the drug because of adverse events. Two publications evaluated the cost effectiveness of Dalbavancin and found it to save about &9000 per patient, the saving being mainly due to reduced length of hospital stay. Dalbavancin appears to be an efficacious, safe and cost-effective option for sequential treatment of endocarditis caused by Staph aureus and other Gram-positive organisms. All Authors: No reported disclosures